Nirmatrelvir/ritonavir (Slovenian Wikipedia)
Analysis of information sources in references of the Wikipedia article "Nirmatrelvir/ritonavir" in Slovenian language version.
refsWebsite
Global rank
Slovenian rank
1st place
2nd place
3,984th place
2,156th place
615th place
3,307th place
34th place
120th place
99th place
331st place
49th place
97th place
137th place
646th place
low place
low place
low place
7,855th place
low place
low place
5,063rd place
7,550th place
acsh.org
- Bloom J (2. december 2021). »How Does Pfizer's Pavloxid Compare With Ivermectin?«. American Council on Science and Health. Arhivirano iz prvotnega spletišča dne 12. decembra 2021. Pridobljeno 12. decembra 2021.
bloomberg.com
- »Pfizer Says Patients Who Relapse After Covid Pill Can Repeat Treatment«. Bloomberg. 3. maj 2022. Pridobljeno 21. maja 2022.
businesswire.com
- »Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment« (tiskovna objava). Pfizer. 22. december 2021. Pridobljeno 22. decembra 2021 – prek Business Wire.
- »Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death« (tiskovna objava). Pfizer. 14. december 2021. Pridobljeno 25. decembra 2021 – prek Business Wire.
canada.ca
canada.ca
- »Health Canada authorizes Paxlovid for patients with mild to moderate COVID-19 at high risk of developing serious disease«. Health Canada (tiskovna objava). 17. januar 2022. Pridobljeno 24. aprila 2022.
covid-vaccine.canada.ca
- »Paxlovid«. COVID-19 vaccines and treatments portal. 17. januar 2022. Pridobljeno 25. aprila 2022.
chrisvoncsefalvay.com
- von Csefalvay C (27. november 2021). »Why Paxlovid is not Pfizermectin«. Chris von Csefalvay: Bits and Bugs. Arhivirano iz prvotnega spletišča dne 9. januarja 2022. Pridobljeno 9. januarja 2022.
clinicaltrialsarena.com
- »Pfizer begins dosing in Phase II/III trial of antiviral drug for Covid-19«. Clinical Trials Arena. 2. september 2021.
doi.org
- Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, in sod. (Februar 2022). »Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19«. The New England Journal of Medicine. doi:10.1056/NEJMoa2118542. PMC 8908851. PMID 35172054.
- Robinson J (april 2022). »PANORAMIC trial to enlist 17,500 more patients as researchers add second COVID-19 antiviral«. The Pharmaceutical Journal. doi:10.1211/PJ.2022.1.138635.
{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
europa.eu
ema.europa.eu
- »Paxlovid EPAR«. Evropska agencija za zdravila (EMA). 24. januar 2022. Pridobljeno 3. februarja 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- https://www.ema.europa.eu/en/documents/overview/paxlovid-epar-medicine-overview_sl.pdf EPAR Paxlovid (PF-07321332/ritonavir) Pregled zdravila Paxlovid in zakaj je odobreno v EU, Evropska agencija za zdravila, januar 2022, vpogled: 26. 5. 2022.
- »EMA issues advice on use of Paxlovid (PF-07321332 and ritonavir) for the treatment of COVID-19: rolling review starts in parallel« (tiskovna objava). Evropska agencija za zdravila (EMA). 16. december 2021. Pridobljeno 6. januarja 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
ec.europa.eu
- »Paxlovid«. Union Register of medicinal products. 28. januar 2022. Pridobljeno 24. aprila 2022.
fda.gov
- »FDA Authorizes First Oral Antiviral for Treatment of COVID-19«. U.S. Food and Drug Administration (FDA) (tiskovna objava). 22. december 2021. Pridobljeno 22. decembra 2021.
Članek vsebuje besedilo iz tega vira, ki je v javni domeni. - »Frequently Asked Questions on the Emergency Use Authorization for Paxlovid for Treatment of COVID-19« (PDF). U.S. Food and Drug Administration (FDA). 22. december 2021.
- »FDA Updates on Paxlovid for Health Care Providers«. FDA. 4. maj 2022. Pridobljeno 21. maja 2022.
- CDER Scientific Review Supporting EUA (PDF) (poročilo). U.S. Food and Drug Administration (FDA).
gov.uk
- »Summary of Product Characteristics for Paxlovid«. Medicines and Healthcare products Regulatory Agency (MHRA). 31. december 2021. Pridobljeno 31. decembra 2021.
- »Regulatory approval of Paxlovid«. Medicines and Healthcare products Regulatory Agency (MHRA). 31. december 2021. Pridobljeno 31. decembra 2021.
- »Oral COVID-19 antiviral, Paxlovid, approved by UK regulator« (tiskovna objava). Medicines and Healthcare products Regulatory Agency. 31. december 2021.
nbcnews.com
- »Pfizer antiviral pills may be risky with other medications«. ABC News. 26. december 2021. Pridobljeno 4. februarja 2022.
nih.gov
dailymed.nlm.nih.gov
- »Paxlovid- nirmatrelvir and ritonavir kit«. DailyMed. Pridobljeno 30. decembra 2021.
covid19treatmentguidelines.nih.gov
- »Ritonavir-Boosted Nirmatrelvir (Paxlovid)«. National Institutes of Health. 24. februar 2022. Arhivirano iz spletišča dne 23. aprila 2022. Pridobljeno 25. aprila 2022.
ncbi.nlm.nih.gov
- Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, in sod. (Februar 2022). »Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19«. The New England Journal of Medicine. doi:10.1056/NEJMoa2118542. PMC 8908851. PMID 35172054.
pubmed.ncbi.nlm.nih.gov
- Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, in sod. (Februar 2022). »Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19«. The New England Journal of Medicine. doi:10.1056/NEJMoa2118542. PMC 8908851. PMID 35172054.
pharmaceutical-journal.com
- Robinson J (april 2022). »PANORAMIC trial to enlist 17,500 more patients as researchers add second COVID-19 antiviral«. The Pharmaceutical Journal. doi:10.1211/PJ.2022.1.138635.
{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
reuters.com
- »Pfizer says COVID treatment Paxlovid fails to prevent infection of household members«. Reuters. 29. april 2022. Pridobljeno 21. maja 2022.
sciencebasedmedicine.org
- Gorski D (15. november 2021). »Pfizer's new COVID-19 protease inhibitor drug is not just 'repackaged ivermectin'«. Science-Based Medicine.
tga.gov.au
tga.gov.au
- »Paxlovid APMDS«. Therapeutic Goods Administration (TGA). 21. januar 2022. Arhivirano iz prvotnega spletišča dne 5. februarja 2022. Pridobljeno 5. februarja 2022.
- »AusPAR: nirmatrelvir/ritonavir«. Therapeutic Goods Administration (TGA). 25. januar 2022. Arhivirano iz prvotnega spletišča dne 24. marca 2022. Pridobljeno 23. marca 2022.
ebs.tga.gov.au
washingtonpost.com
- »The U.S. Is Doing Too Little to Monitor Paxlovid Use«. The Washington Post. 4. maj 2022. Pridobljeno 21. maja 2022.
web.archive.org
- »Paxlovid APMDS«. Therapeutic Goods Administration (TGA). 21. januar 2022. Arhivirano iz prvotnega spletišča dne 5. februarja 2022. Pridobljeno 5. februarja 2022.
- »AusPAR: nirmatrelvir/ritonavir«. Therapeutic Goods Administration (TGA). 25. januar 2022. Arhivirano iz prvotnega spletišča dne 24. marca 2022. Pridobljeno 23. marca 2022.
- »Ritonavir-Boosted Nirmatrelvir (Paxlovid)«. National Institutes of Health. 24. februar 2022. Arhivirano iz spletišča dne 23. aprila 2022. Pridobljeno 25. aprila 2022.
- Bloom J (2. december 2021). »How Does Pfizer's Pavloxid Compare With Ivermectin?«. American Council on Science and Health. Arhivirano iz prvotnega spletišča dne 12. decembra 2021. Pridobljeno 12. decembra 2021.
- von Csefalvay C (27. november 2021). »Why Paxlovid is not Pfizermectin«. Chris von Csefalvay: Bits and Bugs. Arhivirano iz prvotnega spletišča dne 9. januarja 2022. Pridobljeno 9. januarja 2022.